|
|
|
|
||
Re: About KRTX's schizophrenia drug & NuplazidThis is not the first time that the market has been irrationally exuberant about a biotech company. -Puma Biotech was once $200 per share. Today it is trading under $8. -Last year Sarepta topped $161. Today it trades under $100. -Clovis was once $114. Today it hovers in the $6 to $7 range. -Sage was $190 in July. Today it is $146. The KRTX news is surely exciting, as no one to my knowledge had put much faith in muscarinic-receptor targeting as a means of battling psychosis. This could turn out to be one hell of a breakthrough. There is, nevertheless, much more work for Karuna to do. Even if everything goes perfectly to plan -- and often it doesn't -- its drug will not be on the market until late 2023 at the earliest. By that time Nuplazid will probably be netting Acadia annual sales of between $2 and $3 billion. We Acadians will have our Seattle Genetics moment. I promise. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
15944 | Re: About KRTX's schizophrenia drug & Nuplazid | Nazaretti | 1 | 11/18/2019 3:09:35 PM |
15947 | Re: About KRTX's schizophrenia drug & Nuplazid | longusa | 5 | 11/18/2019 3:33:47 PM |